Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied Drug/Drug Interaction (DDI) Probe Compounds

NCT02641899 is registered in ClinicalTrials.gov with Intarcia Therapeutics as lead sponsor.

NCT NCT02641899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02641899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied Drug/Drug Interaction (DDI) Probe Compounds
Lead sponsor
Intarcia Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2015
Completion date
March 31, 2016
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy